MT-101 is under clinical development by Myeloid Therapeutics and currently in Phase II for Mycosis Fungoides. According to GlobalData, Phase II drugs for Mycosis Fungoides have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MT-101 overview
MT-101 is under development for the treatment of peripheral T cell lymphoma (PTCL), angioimmunoblastic T cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), and ALK-positive anaplastic large cell lymphoma (ALCL), mycosis fungoides. The drug candidate comprises of engineered myeloid cells express chimeric antigen receptor (CAR). It acts by targeting cells expressing CD5. It is developed based on Activate Target Attack Kill (ATAK) platform. It is administered through intravenous route.
Myeloid Therapeutics overview
Myeloid Therapeutics, Inc., a US based company harnessing and reprogramming myeloid cells to treat cancers.
For a complete picture of MT-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - MT-101 in Mycosis Fungoides
Premium Insights
The gold standard of business intelligence.
